Probiotics in Enteral Feeding in Critically Ill Patients

Sponsor
University of Malaya (Other)
Overall Status
Completed
CT.gov ID
NCT01792401
Collaborator
(none)
49
1
2
11
4.5

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the effect of probiotics in enteral nutrition on improving gut function, inflammatory markers and clinical outcomes in critically ill patients admitted to the intensive care unit.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Gut failure in critically ill patients is common. Enteral feeding is one of the preferred routes for nutrition support to maintain gut function. However, enteral nutrition is not without complications such as alterations in gut transit time and gut eco-culture. Enteral nutrition supplemented with a probiotic offers a possible solution to modulating this ecosystem. Objectives: The primary aim of this study was to investigate the effect of probiotics in enteral feeding on improving the gut function, inflammatory markers and clinical outcomes in critically ill patients. Subjects and Methods: Forty-nine patients that were admitted to the intensive care unit in University Malaya Medical Center requiring enteral feeding were randomized to receive either probiotics or a placebo. Patients remained in the intensive care unit for more than 7 days and were examined prior to the start of enteral feeding and on day 8. Return of gut function was assessed by the time needed to achieve caloric requirement. Inflammatory markers including the White Cell Count and C-reactive protein levels were tested on day 1 and day 8. Clinical outcome was assessed by number of days of ventilation and total days in intensive care unit.

Study Design

Study Type:
Interventional
Actual Enrollment :
49 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Probiotics in Enteral Feeding in Critically Ill Patients
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Dec 1, 2012
Actual Study Completion Date :
Dec 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Patients on enteral feeding in intensive care units are administered a placebo

Drug: Placebo

Active Comparator: Probiotics

Patients on enteral feeding in intensive care unit are given a probiotic

Drug: Probiotics

Outcome Measures

Primary Outcome Measures

  1. Improve the time to return of gut function in patient on enteral feeding in intensive care unit [Time required to achieve maximum enteral feeding with a minimum of 48 hours]

    Probiotic/placebo administered once enteral feeding is started, and the hours needed to achieve maximum feeding is calculated in hours

Secondary Outcome Measures

  1. Inflammatory markers [7-14 days]

    Measure of inflammatory markers are obtained from patients at the start and at the end of probiotic/placebo administrations.

Other Outcome Measures

  1. Clinical Outcome [Patients will be followed up throughtout their duration of intensive care stay, or a minimum of 1-14 days]

    Number of days in intensive care and number of ventilation days are calculated at the end of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admitted to intensive care unit

  • Expected stay of more than 48 hours

  • On enteral feeding

  • Consent obtained from patient/relative

Exclusion Criteria:
  • Patients on immuno-suppressive drugs

  • Patients with hematological diseases

  • Pregnant females

  • Do not consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Malaya Medical Center Kuala Lumpur Malaysia 59100

Sponsors and Collaborators

  • University of Malaya

Investigators

  • Principal Investigator: Ausama A Malik, MS,MBBS(Mal), University Malaya Medical Center
  • Study Chair: Kin Fah Chin, FRCS (Glasg), University Malaya
  • Study Chair: Vineya Rai Hakumat Rai, M. Anes,MBBS, University Malaya
  • Study Chair: Chee Loong Yeap, MS,MBBS(Mal), University Malaya
  • Study Chair: Peng Choong Lau, MS,MBBS(Mal), University Malaya
  • Study Chair: Eng Hong Pok, MS,MBBS(Mal), University Malaya
  • Study Chair: Gowri Rajandram, Phd(Aust), University Malaya

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ausama A Malik, Surgeon/Clinical Specialist, University of Malaya
ClinicalTrials.gov Identifier:
NCT01792401
Other Study ID Numbers:
  • PEFCIP
First Posted:
Feb 15, 2013
Last Update Posted:
Feb 15, 2013
Last Verified:
Feb 1, 2013
Keywords provided by Ausama A Malik, Surgeon/Clinical Specialist, University of Malaya
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2013